All In Biotech

Drug Trial Radar · NCT01794143

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study

Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 7,850 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,850

Actual

Start

May 2013

Primary completion

Apr 30, 2021

Study completion Apr 30, 2021

Sponsor

Lead sponsor
GRADE Study GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Heart, Lung, and Blood Institute (NHLBI); Centers for Disease Control and Prevention
First posted
Feb 18, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The GRADE Study is a pragmatic, unmasked clinical trial that will compare commonly used diabetes medications, when combined with metformin, on glycemia-lowering effectiveness and patient-centered outcomes.

Conditions

  • Type 2 Diabetes
  • Comparative Effectiveness of Glycemia-lowering Medications

Interventions

  • Sulfonylurea (glimepiride)Drug

    Used in accordance with labeling and/or usual practice.

  • DPP-4 inhibitor (sitagliptin)Drug

    Used in accordance with labeling and/or usual practice

  • GLP-1 receptor agonist (liraglutide)Drug

    Used in accordance with labeling and/or usual practice.

  • Insulin (glargine)Drug

    Used in accordance with labeling and/or usual practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study MedicationTime frame: Quarterly for 4 to 7 years
  2. HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study MedicationTime frame: Quarterly, 4-7 years

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama-Birmingham

    Birmingham, Alabama

  • Southwestern American Indian Center

    Phoenix, Arizona

  • Veterans Medical Research Foundation, San Diego (San Diego VA)

    San Diego, California

  • University of Colorado

    Denver, Colorado

  • Yale University School of Medicine

    New Haven, Connecticut

  • South Florida VA Foundation (Miami VA)

    Miami, Florida

  • Atlanta VA Medical Center

    Decatur, Georgia

  • Kaiser Permanente of Georgia

    Duluth, Georgia

  • Pacific Health Research and Education Institute (VA Pacific Islands)

    Honolulu, Hawaii

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • University of Iowa

    Iowa City, Iowa

  • Pennington Biomedical Research Center

    Baton Rouge, Louisiana

  • MedStar Health Research Institute

    Hyattsville, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • International Diabetes Center

    Minneapolis, Minnesota

  • University of Minnesota

    Minneapolis, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • University of Nebraska

    Omaha, Nebraska

  • University of New Mexico School of Medicine

    Albuquerque, New Mexico

  • State University of New York (SUNY)-Downstate Medical Center

    Brooklyn, New York

  • Columbia University Naomi Berrie Diabetes Center

    New York, New York

  • Mount Sinai St. Luke's Hospital

    New York, New York

  • Albert Einstein College of Medicine

    The Bronx, New York

  • Duke University Medical Center

    Durham, North Carolina

  • University of North Carolina Diabetes Care Center

    Durham, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Case Western Reserve University School of Medicine

    Cleveland, Ohio

  • Kaiser Permanente Northwest

    Portland, Oregon

  • Oregon Health and Science University

    Portland, Oregon

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Baylor Endocrine Center

    Dallas, Texas

  • University of Texas-Southwestern Medical Center

    Dallas, Texas

  • Baylor College of Medicine

    Houston, Texas

  • University of Texas Health Science Center

    San Antonio, Texas

  • Seattle Institute for Biomedical and Clinical Research

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.